Overview

Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer

Status:
Not yet recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

The aim of the trial is to investigate the clinical efficacy and toxicity of perioperative chemotherapy with leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who receive a curative surgery.

Phase:

Phase 2

Details

Lead Sponsor:

National Cheng-Kung University Hospital

Collaborators:

China Medical University Hospital
Kaohsiung Veterans General Hospital.
Taipei Veterans General Hospital, Taiwan
TTY Biopharm

Treatments:

Docetaxel
Leucovorin
Levoleucovorin
Oxaliplatin